About IRIDEX (NASDAQ:IRIX)
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700
Debt
Debt-to-Equity RatioN/A
Current Ratio3.80%
Quick Ratio2.89%
Price-To-Earnings
Trailing P/E Ratio-5.14
Forward P/E Ratio-5.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$41.59 million
Price / Sales1.62
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book2.20
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-12,860,000.00
Net Margins-30.93%
Return on Equity-35.98%
Return on Assets-28.84%
Miscellaneous
Employees116
Outstanding Shares11,630,000
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) posted its earnings results on Thursday, March, 8th. The medical equipment provider reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.17. The medical equipment provider had revenue of $10.24 million for the quarter, compared to the consensus estimate of $10.22 million. IRIDEX had a negative return on equity of 35.98% and a negative net margin of 30.93%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What price target have analysts set for IRIX?
1 Wall Street analysts have issued twelve-month price targets for IRIDEX's stock. Their forecasts range from $13.00 to $13.00. On average, they expect IRIDEX's stock price to reach $13.00 in the next year. View Analyst Ratings for IRIDEX.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include Zynex (ZYXI), Biolife Solutions (BLFS), Viveve Medical (VIVE), Second Sight Medical (EYES), Edap Tms (EDAP), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Digirad (DRAD), Aradigm (ARDM), Dynatronics (DYNT), EnteroMedics (RSLS), CHF Solutions (CHFS), FC Global Realty (FCRE), Trimedyne (TMED), IMRIS (IMRSQ) and Echo Therapeutics (ECTE).
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman, Chief Exec. Officer and Pres (Age 69)
- Mr. Atabak Mokari, Chief Financial Officer and VP of Corp. Devel. (Age 41)
- Dr. George R. Marcellino Ph.D., VP of Clinical Affairs & Director (Age 69)
- Mr. Timothy D. Buckley, VP of Global Marketing & Bus. Devel. (Age 43)
- Ms. Stacie Rodgers, VP of HR
Has IRIDEX been receiving favorable news coverage?
Media coverage about IRIX stock has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. IRIDEX earned a media sentiment score of 0.23 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 44.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $5.81.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $65.69 million and generates $41.59 million in revenue each year. The medical equipment provider earns $-12,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. IRIDEX employs 116 workers across the globe.
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
IRIDEX (NASDAQ:IRIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for IRIDEX in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 123.75%. The high price target for IRIX is $13.00 and the low price target for IRIX is $13.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.00 | $13.00 | $13.00 | $20.00 |
| Price Target Upside: | 123.75% upside | 52.22% upside | 52.22% upside | 51.29% upside |
IRIDEX (NASDAQ:IRIX) Consensus Price Target History
IRIDEX (NASDAQ:IRIX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/3/2017 | Roth Capital | Reiterated Rating | Buy -> Buy | $13.00 | N/A |  |
(Data available from 4/20/2016 forward)
IRIDEX (NASDAQ:IRIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IRIDEX (NASDAQ IRIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.01%
Institutional Ownership Percentage: 48.23%
IRIDEX (NASDAQ IRIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | Romeo R Dizon | Insider | Sell | 2,806 | $5.86 | $16,443.16 | | |
| 12/12/2017 | William M Moore | CEO | Buy | 5,000 | $7.84 | $39,200.00 | | |
| 9/15/2017 | William M Moore | Chairman | Buy | 1,800 | $9.42 | $16,956.00 | 372,434 | |
| 3/15/2017 | Romeo R Dizon | Insider | Sell | 2,811 | $13.16 | $36,992.76 | 17,289 | |
| 11/16/2016 | Romeo R Dizon | Insider | Sell | 584 | $16.04 | $9,367.36 | 20,434 | |
| 9/12/2016 | Romeo R Dizon | Insider | Sell | 125 | $15.00 | $1,875.00 | 20,163 | |
| 9/7/2016 | Ruediger Naumann-Etienne | Director | Sell | 9,513 | $14.75 | $140,316.75 | 71,433 | |
| 9/2/2016 | Ruediger Naumann-Etienne | Director | Sell | 2,513 | $14.73 | $37,016.49 | 71,433 | |
| 8/23/2016 | Romeo R Dizon | Insider | Sell | 875 | $14.52 | $12,705.00 | 20,975 | |
| 8/19/2016 | Romeo R Dizon | Insider | Sell | 7,896 | $13.52 | $106,753.92 | 20,123 | |
| 8/16/2016 | George R Marcellino | Director | Sell | 2,513 | $13.57 | $34,101.41 | 1,289 | |
| 8/16/2016 | Romeo R Dizon | Insider | Sell | 839 | $13.70 | $11,494.30 | 20,100 | |
| 6/6/2016 | Ronald Steckel | VP | Sell | 625 | $13.52 | $8,450.00 | 66,250 | |
| 5/17/2016 | Ronald Steckel | VP | Sell | 4,583 | $12.81 | $58,708.23 | 68,958 | |
| 3/8/2016 | Ronald Steckel | VP | Sell | 12,000 | $10.45 | $125,400.00 | 75,125 | |
| 11/19/2015 | William M Moore | CEO | Buy | 10,000 | $9.83 | $98,300.00 | 290,931 | |
| 9/25/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 52,042 | $7.05 | $366,896.10 | | |
| 9/10/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 11,866 | $6.95 | $82,468.70 | | |
| 9/4/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 10,304 | $6.81 | $70,170.24 | | |
| 9/2/2015 | Ronald Steckel | VP | Sell | 1,875 | $6.80 | $12,750.00 | 28,875 | |
| 8/21/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 20,651 | $7.16 | $147,861.16 | | |
| 8/19/2015 | James H. Mackaness | CFO | Sell | 2,373 | $7.15 | $16,966.95 | 45,052 | |
| 8/19/2015 | Ronald Steckel | VP | Sell | 1,751 | $7.14 | $12,502.14 | 28,875 | |
| 8/18/2015 | James H. Mackaness | CFO | Sell | 2,627 | $7.10 | $18,651.70 | 44,558 | |
| 8/17/2015 | James H. Mackaness | CFO | Sell | 2,235 | $7.05 | $15,756.75 | 44,558 | |
| 8/14/2015 | James H Mackaness | CFO | Sell | 7,765 | $6.99 | $54,277.35 | | |
| 8/14/2015 | Ronald Steckel | VP | Sell | 1,458 | $7.00 | $10,206.00 | | |
| 7/24/2015 | Associates & Paragon A Paragon | Major Shareholder | Buy | 40,403 | $7.01 | $283,225.03 | | |
| 6/17/2015 | Ronald Steckel | VP | Sell | 1,666 | $8.77 | $14,610.82 | | |
| 5/20/2015 | James H Mackaness | CFO | Sell | 2,000 | $9.80 | $19,600.00 | | |
| 5/18/2015 | Ronald Steckel | VP | Sell | 1,667 | $9.33 | $15,553.11 | | |
| 4/20/2015 | Ronald Steckel | VP | Sell | 1,447 | $9.79 | $14,166.13 | | |
| 4/17/2015 | Ronald Steckel | VP | Sell | 1,667 | $9.86 | $16,436.62 | | |
| 3/17/2015 | Ronald Steckel | VP | Sell | 11,358 | $10.08 | $114,488.64 | | |
| 3/10/2015 | Ronald Steckel | VP | Sell | 1,250 | $10.03 | $12,537.50 | | |
| 2/17/2015 | Ronald Steckel | VP | Sell | 1,650 | $9.79 | $16,153.50 | | |
| 1/20/2015 | Ronald Steckel | VP | Sell | 1,650 | $9.03 | $14,899.50 | | |
| 12/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.52 | $14,058.00 | | |
| 11/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.28 | $13,662.00 | | |
| 11/6/2014 | William M Moore | Director | Buy | 5,000 | $7.79 | $38,950.00 | | |
| 10/12/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 17,237 | $8.11 | $139,792.07 | | |
| 10/10/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 12,798 | $8.02 | $102,639.96 | | |
| 9/5/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 8,432 | $7.99 | $67,371.68 | | |
| 8/29/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 4,272 | $7.92 | $33,834.24 | | |
| 8/22/2014 | James B Hawkins | Director | Sell | 600 | $8.03 | $4,818.00 | | |
| 8/18/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.00 | $13,200.00 | | |
| 8/15/2014 | James B Hawkins | Director | Sell | 14,400 | $8.10 | $116,640.00 | | |
| 8/14/2014 | James B Hawkins | Director | Sell | 2,714 | $8.08 | $21,929.12 | | |
| 8/13/2014 | James B Hawkins | Director | Sell | 9,786 | $8.11 | $79,364.46 | | |
| 8/11/2014 | Garrett A Garrettson | Director | Sell | 2,810 | $8.30 | $23,323.00 | | |
| 7/31/2014 | Ronald Steckel | VP | Sell | 761 | $8.00 | $6,088.00 | | |
| 7/21/2014 | James H Mackaness | CFO | Sell | 1,000 | $7.62 | $7,620.00 | | |
| 6/23/2014 | James H Mackaness | CFO | Sell | 2,000 | $8.24 | $16,480.00 | | |
| 6/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.20 | $13,530.00 | | |
| 6/6/2014 | Catalyst Fund Ix L.P Blueline | Director | Buy | 7,390 | $8.32 | $61,484.80 | | |
| 6/3/2014 | William M Moore | CEO | Buy | 5,000 | $8.48 | $42,400.00 | | |
| 5/21/2014 | James H Mackaness | CFO | Sell | 3,000 | $8.73 | $26,190.00 | | |
| 5/19/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.82 | $14,553.00 | | |
| 5/9/2014 | William M Moore | CEO | Buy | 5,000 | $8.40 | $42,000.00 | | |
| 4/22/2014 | James H Mackaness | CFO | Sell | 4,000 | $8.74 | $34,960.00 | | |
| 4/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.88 | $14,652.00 | | |
| 3/21/2014 | James H Mackaness | CFO | Sell | 4,000 | $9.03 | $36,120.00 | | |
| 3/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $9.07 | $14,965.50 | | |
| 2/18/2014 | Ronald Steckel | VP | Sell | 1,650 | $8.60 | $14,190.00 | | |
| 1/17/2014 | Ronald Steckel | VP | Sell | 1,650 | $10.42 | $17,193.00 | | |
| 12/17/2013 | Ronald Steckel | VP | Sell | 1,650 | $8.56 | $14,124.00 | | |
| 12/2/2013 | James H Mackaness | CFO | Sell | 10,000 | $10.52 | $105,200.00 | | |
| 9/6/2013 | Ruediger Naumann-Etienne | Director | Buy | 3,600 | $5.99 | $21,564.00 | | |
| 8/9/2013 | William M Moore | CEO | Buy | 10,000 | $5.88 | $58,800.00 | | |
| 6/19/2013 | Eduardo Arias | VP | Sell | 22,768 | $5.43 | $123,630.24 | | |
| 6/18/2013 | James H Mackaness | CFO | Sell | 19,862 | $4.58 | $90,967.96 | | |
| 6/17/2013 | Eduardo Arias | VP | Sell | 4,532 | $5.39 | $24,427.48 | | |
| 6/14/2013 | James H Mackaness | CFO | Sell | 10,568 | $5.38 | $56,855.84 | | |
| 6/13/2013 | James H Mackaness | CFO | Sell | 1,400 | $5.30 | $7,420.00 | | |
| 6/11/2013 | Eduardo Arias | VP | Sell | 1,000 | $5.61 | $5,610.00 | | |
| 6/11/2013 | James H Mackaness | CFO | Sell | 1,200 | $5.61 | $6,732.00 | | |
| 6/10/2013 | Eduardo Arias | VP | Sell | 2,400 | $5.38 | $12,912.00 | | |
| 6/10/2013 | James H Mackaness | CFO | Sell | 6,970 | $5.36 | $37,359.20 | | |
| 6/6/2013 | William M Moore | CEO | Buy | 2,000 | $5.42 | $10,840.00 | | |
| 5/17/2013 | Eduardo Arias | VP | Sell | 10,000 | $6.30 | $63,000.00 | | |
| 3/8/2013 | Ruediger Naumann-Etienne | Director | Buy | 2,400 | $4.80 | $11,520.00 | | |
| 3/7/2013 | William M Moore | CEO | Buy | 10,000 | $4.66 | $46,600.00 | | |
| 9/6/2012 | William M Moore | CEO | Buy | 10,000 | $3.76 | $37,600.00 | | |
| 8/15/2012 | Catalyst Fund Ix L.P Blueline | Major Shareholder | Buy | 60,900 | $3.19 | $194,271.00 | | |
(Data available from 1/1/2013 forward)
IRIDEX (NASDAQ IRIX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | IRIDEX to Report First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 19 at 4:29 PM |
| IRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors
finance.yahoo.com - April 16 at 4:15 PM |
 | IRIDEX (IRIX) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:36 PM |
| Contrasting IRIDEX (IRIX) & Cutera (CUTR)
www.americanbankingnews.com - March 31 at 5:37 AM |
| Iridex Receives CE Mark for Transilluminated Probe
finance.yahoo.com - March 20 at 9:53 AM |
| Edited Transcript of IRIX earnings conference call or presentation 8-Mar-18 10:00pm GMT
finance.yahoo.com - March 18 at 9:36 AM |
| IRIDEX Co. (IRIX) Insider Romeo R. Dizon Sells 2,806 Shares
www.americanbankingnews.com - March 14 at 8:46 PM |
| IRIDEX (IRIX) Issues Quarterly Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - March 9 at 12:38 AM |
| IRIDEX Announces 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 8 at 5:05 PM |
| IRIDEX (IRIX) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:12 AM |
| Pulse Biosciences (PLSE) versus IRIDEX (IRIX) Financial Review
www.americanbankingnews.com - February 28 at 11:12 PM |
| IRIDEX to Present at the 30th Annual Roth Conference
finance.yahoo.com - February 27 at 4:52 PM |
| IRIDEX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Iridex Corp. To Contact The Firm
finance.yahoo.com - February 27 at 4:52 PM |
| Analysts Anticipate IRIDEX Co. (IRIX) to Post ($0.25) EPS
www.americanbankingnews.com - February 27 at 1:36 AM |
| IRIDEX Issues Voluntary Recall of TruFocus LIO Premiere™ Laser Indirect Ophthalmoscope
finance.yahoo.com - February 23 at 4:44 PM |
| IRIDEX to Report Fourth Quarter and 2017 Financial Results on March 8, 2018
finance.yahoo.com - February 20 at 9:15 AM |
| Quidel (QDEL) and IRIDEX (IRIX) Critical Comparison
www.americanbankingnews.com - February 19 at 3:20 AM |
| Zacks: IRIDEX Co. (IRIX) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 23 at 8:22 AM |
| Head-To-Head Analysis: Mazor Robotics (MZOR) and IRIDEX (IRIX)
www.americanbankingnews.com - January 19 at 5:32 PM |
| IRIDEX Announces Infringement Lawsuit Against Quantel
finance.yahoo.com - January 9 at 11:18 AM |
| Zacks: Brokerages Set $13.00 Target Price for IRIDEX Co. (IRIX)
www.americanbankingnews.com - January 8 at 5:34 PM |
| IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year
finance.yahoo.com - January 8 at 11:00 AM |
| What Are Analysts Saying About IRIDEX Corporation’s (NASDAQ:IRIX) Future?
finance.yahoo.com - January 6 at 9:16 AM |
| What You Must Know About IRIDEX Corporation’s (NASDAQ:IRIX) Financial Health
finance.yahoo.com - December 29 at 10:56 AM |
| ETFs with exposure to IRIDEX Corp. : December 27, 2017
finance.yahoo.com - December 27 at 1:28 PM |
| IRIDEX Corp. :IRIX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:11 PM |
| IRIDEX (IRIX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - December 21 at 12:14 AM |
| IRIDEX Co. (IRIX) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 16 at 11:30 AM |
| William M. Moore Acquires 5,000 Shares of IRIDEX Co. (IRIX) Stock
www.americanbankingnews.com - December 15 at 9:44 PM |
| IRIDEX (IRIX) & Accelerate Diagnostics (AXDX) Head-To-Head Comparison
www.americanbankingnews.com - December 4 at 1:34 AM |
| Head to Head Review: Digirad (DRAD) & IRIDEX (IRIX)
www.americanbankingnews.com - November 29 at 9:44 PM |
| Brokerages Anticipate IRIDEX Corporation (IRIX) to Announce ($0.21) Earnings Per Share
www.americanbankingnews.com - November 28 at 7:56 AM |
| Critical Analysis: IRIDEX Corporation (IRIX) & Mindray Medical International (MR)
www.americanbankingnews.com - November 18 at 5:20 PM |
| Comparing Digirad Corporation (DRAD) and IRIDEX Corporation (IRIX)
www.americanbankingnews.com - November 9 at 3:38 AM |
| IRIDEX Corporation (IRIX) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - November 3 at 10:48 AM |
| Edited Transcript of IRIX earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 3 at 8:44 AM |
| ETFs with exposure to IRIDEX Corp. : October 27, 2017
finance.yahoo.com - October 28 at 7:08 AM |
| IRIDEX to Present at Upcoming Investor Conferences
finance.yahoo.com - October 26 at 7:37 PM |
| IRIDEX Corporation (IRIX) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - October 26 at 6:10 AM |
| IRIDEX to Report Third Quarter 2017 Financial Results on November 2, 2017
finance.yahoo.com - October 20 at 12:40 AM |
| ETFs with exposure to IRIDEX Corp. : October 9, 2017
finance.yahoo.com - October 9 at 8:00 PM |
| IRIDEX Corp. :IRIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 11:55 PM |
| Analyzing IRIDEX Corporation (IRIX) and Thermo Fisher Scientific (TMO)
www.americanbankingnews.com - September 30 at 12:26 PM |
| IRIDEX Corporation (IRIX) Chairman Buys $16,956.00 in Stock
www.americanbankingnews.com - September 18 at 8:32 PM |
| Analyzing IRIDEX Corporation (IRIX) and Alliance HealthCare Services (AIQ)
www.americanbankingnews.com - September 18 at 12:30 AM |
| IRIDEX Corporation (IRIX) & Its Rivals Head to Head Analysis
www.americanbankingnews.com - September 17 at 8:30 PM |
| Is It The Right Time To Buy IRIDEX Corporation (IRIX)?
finance.yahoo.com - September 11 at 8:42 PM |
| Critical Survey: IRIDEX Corporation (IRIX) & The Competition
www.americanbankingnews.com - September 9 at 2:08 PM |
| Head to Head Survey: Illumina (ILMN) and IRIDEX Corporation (IRIX)
www.americanbankingnews.com - September 9 at 4:06 AM |
| Financial Analysis: IRIDEX Corporation (IRIX) versus Viveve Medical (VIVE)
www.americanbankingnews.com - September 5 at 8:34 AM |
IRIDEX (NASDAQ:IRIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IRIDEX (NASDAQ:IRIX) Income Statement, Balance Sheet and Cash Flow Statement
IRIDEX (NASDAQ IRIX) Stock Chart for Friday, April, 20, 2018
Loading chart…
